The News
Catch the latest updates as CTMC drives innovation in cell therapy to accelerate development and manufacturing
to impact patients sooner
Press Releases
QIMR Berghofer and CTMC announce strategic collaboration in cell and gene therapy through the CTMC Global Network Alliance
BRISBANE, AUSTRALIA & HOUSTON, TEXAS, 23 JUNE 2026 – QIMR Berghofer and CTMC, a joint venture between Resilience and The University of Texas MD...
Novel CAR T cell therapy developed by UT MD Anderson researchers moves into clinical studies
The novel therapy targets CD94+ relapsed or refractory T/NK cell lymphomas UT MD Anderson received Investigational New Drug clearance from the Food...
CTMC and Einstein Hospital Israelita in Brazil Partner to Launch the Global Cell Therapy Network Alliance
The CTMC Network Alliance aims to democratize and accelerate cell therapies to cancer patients globally Read the full press release: CTMC - Einstein...
Recent News
The Wealthing Podcast
Alicia Castillo Holley hosts Jason Bock on her show. Curative Intent: on Engineering T-Cells, Patient Impact, and Chasing the Impossible. The...
Organizing Digital Systems Around Novel Modalities
By Jason Bock, Ph.D., CEO, and Duane Avant, CTO, CTMC Manufacturing autologous cell therapies requires close coordination with clinical staff, as...
How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?
Read the full article here: Pharma's Almanac
Cell Therapy Manufacturing: A Medicine Maker’s “Dream”
Why CTMC CEO Jason Bock relishes the challenge of solving cell therapy’s most complex manufacturing and delivery problems Read the full article...
Part 2: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez
When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from...
Part 1: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez
The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the...
Base to Base biotech podcast #55: The circular supply chain
CTMC is a joint venture between Resilience and the MD Anderson Cancer Center. It works like an internal manufacturing group, adapting to change...
Pairing up to advance CAR T cell therapies: a dual-targeting approach to solid tumours
A partnership between Link Cell Therapies and CTMC is advancing next-generation CAR T therapies for solid tumours by combining dual-targeting...
2026 Cell and Gene Therapy Predictions
For CGTs, this will be the year where the rubber meets the road, according to industry thought leaders Read all the predictions here:...